The National Institute for Health and Care Excellence (NICE) has recommended nemolizumab (Nemluvio, Galderma) for routine funding across England and Wales for moderate-to-severe atopic dermatitis (AD) in its final draft guidance.
This follows NICE’s recent marketing authorization by the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency for the treatment of moderate-to-severe AD in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years and older with a body weight of at least 30kg, who are candidates for systemic therapy.
“It is hugely positive to have a new treatment option available for atopic dermatitis patients that can help to ease the relentless and unforgiving burden this disease can have on their lives,” says Andrew Pink, PhD, Consultant Dermatologist and the Director of the Adult Clinical Trials Unit at St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust in London, UK, in a news release. “Nemolizumab will be an important addition to the current treatment landscape with its novel mode of action and infrequent dosing regime.”
“National Eczema Society welcomes the NICE decision to recommend nemolizumab for treating moderate-to-severe atopic dermatitis,” says Andrew Proctor, Chief Executive. National Eczema Society. “It’s really important we have a range of treatment options, so patients have the chance of accessing a treatment that works effectively for them.”
